Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C3CF
|
|||
| Former ID |
DIB003479
|
|||
| Drug Name |
SDZ-NVI-085
|
|||
| Synonyms |
Sdz-nvi-085; Sdz nvi-085; 104195-17-7; Sdz nvi 085; 2H-Naphth[2,3-b]-1,4-oxazine, 3,4,4a,5,10,10a-hexahydro-6-methoxy-4-methyl-9-(methylthio)-, (4aR,10aR)-;2H-Naphth[2,3-b]-1,4-oxazine, 3,4,4a,5,10,10a-hexahydro-6-methoxy-4-methyl-9-(methylthio)-, (4aR,10aR)-; SLMAGYSTRWJTMF-TZMCWYRMSA-N; sdznvi-085; AC1L2TWR; SCHEMBL194836; CHEMBL337879; DTXSID60146337; 3,4,4a,5,10,10a-Hexahydro-6-methoxy-4-methyl-9-methylthio-2H-naphth(2,3-b)-1,4-oxazine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Major depressive disorder [ICD-11: 6A70.3; ICD-10: F32.2] | Discontinued in Phase 1 | [1] | |
| Company |
Novartis AG
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H21NO2S
|
|||
| Canonical SMILES |
CN1CCOC2C1CC3=C(C=CC(=C3C2)SC)OC
|
|||
| InChI |
1S/C15H21NO2S/c1-16-6-7-18-14-9-11-10(8-12(14)16)13(17-2)4-5-15(11)19-3/h4-5,12,14H,6-9H2,1-3H3/t12-,14-/m1/s1
|
|||
| InChIKey |
SLMAGYSTRWJTMF-TZMCWYRMSA-N
|
|||
| CAS Number |
CAS 104195-17-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor alpha-1A (ADRA1A) | Target Info | Antagonist | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| AMPK signaling pathway | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Vascular smooth muscle contraction | ||||
| Salivary secretion | ||||
| Panther Pathway | Alpha adrenergic receptor signaling pathway | |||
| Reactome | Adrenoceptors | |||
| G alpha (q) signalling events | ||||
| G alpha (12/13) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Endothelin Pathways | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| AMPK Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001726) | |||
| REF 2 | SDZ NVI 085, an alpha 1A-adrenoceptor agonist with 5-HT2A receptor antagonist properties. Eur J Pharmacol. 1996 Feb 15;297(1-2):83-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.